Menu
About Us
Company Overview
Our Values
Board of Directors
Team
Scientific Advisers
Clinical Advisers
Corporate Directory
Corporate Governance
Pipeline
Clinical Trial
Investor Centre
Welcome
Investor Fact Sheet
ASX Announcements
Reports
Annual Reports
Half Yearly Reports
Quarterly Reports
Top 20 Shareholders
Research Reports
Shareholder Services
Investor FAQs
US Shareholders
Investor Newsletters
Communication
In the News
Presentations
Contact Us
Contact Us
Email Alerts
In the news
Recent Posts
Bulls ‘n Bears interview with Dr Chris Burns
Tumour Response in Sixth Patient Triggers Additional Recruitment in Pancreatic Cancer Trial
FDA Fast Track Designation Granted to Narmafotinib in Pancreatic Cancer
Investor Newsletter | September 2024
Proactive Investors | Interview with Amplia CEO Chris Burns on clinical trial progress
Fifth partial response confirmed in ACCENT trial
Categories
Archive
Company News
Investor Newsletters
Videos
14 Oct 2020
Joint Cancer Therapeutics CRC/AMPLIA Therapeutics Press Release
Read More
09 Oct 2020
Amplia Therapeutics CEO says dosing in its phase one trial is 'enormous' milestone
Read More
09 Oct 2020
Amplia Therapeutics CEO says dosing in its phase one trial is 'enormous' milestone
Read More
1
2
3
4
5
6
